This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineBrentuximab vedotin
an investigational antibody–drug conjugate directed to CD30
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
ECHELON-3: Relapsed/refractory DLBCL (BV + lenalidomide and rituximab vs placebo + lenalidomide and rituximab)
-
Phase 1
-
Phase 2
-
Phase 3
CHECKMATE 436: Relapsed/refractory non-Hodgkin lymphoma (BV + nivolumab)
-
Phase 1
-
Phase 2
-
Phase 3
CHECKMATE 744: Relapsed/refractory second-line Hodgkin lymphoma in AYA patients (BV + nivolumab)
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-015: Frontline Hodgkin lymphoma or PTCL in older patients with significant comorbidities
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-027: Frontline early/advanced stage Hodgkin lymphoma (A + AVD with G-CSF primary prophylaxis or AN + AD)
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-028: Relapsed/refractory Hodgkin lymphoma or PTCL previously treated with BV-containing regimen
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-032: Frontline PTCL with less than 10% CD30 expression (BV + CHP)
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-033: Metastatic solid tumors after progression on PD-1 inhibitor treatment (BV + pembrolizumab)
-
Phase 1
-
Phase 2
-
Phase 3
SGN35-035: Safety of BV and effect on CD4+ count in HIV
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources

High-level synopsis of brentuximab vedotin and ongoing clinical trials

Detailed information about brentuximab vedotin clinical trials
Related Videos
Brentuximab Vedotin in Combination with Nivolumab Proposed Mechanism of Action